Use code ELISA25-262 for 25% off all ELISAs through November.
Bridging ELISA
Detect Therapeutic and Anti-Drug Antibodies for Pharmacokinetic and Immunogenicity Studies
Bridging ELISAs are a type of sandwich ELISA designed for detection of antigens with 2 or more identical binding sites, resulting in the formation of a "bridge" complex. This format is commonly used for quantification of therapeutic antibodies (biologic drugs) as well as anti-drug antibodies resulting from immune response. The bridging ELISA technique is ideally suited for the development of drug antibodies (DA), since it enables both pharmacokinetic characterization and immunogenicity detection.
Like all RayBiotech ELISA kits, our bridging sandwich ELISAs are manufactured in Peachtree Corners, GA, backed by a 100% satisfaction guarantee, and are part of a comprehensive menu of competitively priced products and services to advance AD development and discovery.
The drug antibody (DA) bridging ELISAs employ an antibody specific for the drug coated on a 96-well plate. Standards and samples are pipetted into the wells; the drug molecule binds to the immobilized antibody. The wells are washed and the biotinylated anti-drug antibody is then added. After washing away unbound biotinylated antibodies, HRP-conjugated streptavidin is added to the wells, followed by a substrate solution. The intensity of color development in the wells is proportional to the amount of DA bound.
The anti-drug antibody ADA bridging ELISAs employ a DA coated on a 96-well plate. Standards and samples are pipetted into the wells; the anti-drug antibodies present in the sample bind to the immobilized DA. The wells are washed and the biotinylated antibody drug is then added. After washing away unbound biotinylated antibody drug, HRP-conjugated streptavidin is added to the wells, followed by a substrate solution. The intensity of color development in the wells is proportional to the amount of ADA bound.
How It Works for Drug Antibodies (DA)
How RayBiotech bridging ELISAs detect drug antibodies.
How It Works for Anti-Drug Antibodies (ADA)
How RayBiotech bridging ELISAs detect anti-drug antibodies.
Features
- Reliable, robust sandwich ELISA format
- Assays available for many FDA-approved biologics
- Compatible with serum, plasma, and many other sample types
- Quantifying DA in a variety of matrices
- Pharmacokinetic analysis
- Immunogenicity characterization
- Detection of unwanted immune responses to biotherapeutics
- Custom kits available (contact us for a quote)
Contents of Kit
- 96-well pre-coated strip plate (12x8)
- Wash Buffer Concentrate (20x)
- DA or ADA Standard
- Sample Diluent Buffers
- Labeled Detection Antibody
- HRP-Streptavidin concentrate*
- TMB One-Step Substrate Reagent
- Stop Solution
Bridging ELISA
Showing 1–20 of 140 products
Anti-Nirsevimab ELISA Kit
From: $1,364.00
Nirsevimab ELISA Kit
From: $1,364.00
Anti-Isatuximab ELISA Kit
From: $1,364.00
Isatuximab ELISA Kit
From: $1,364.00
Anti-Tremelimumab ELISA Kit
From: $1,364.00
Tremelimumab ELISA Kit
From: $1,364.00
Anti-Dulaglutide ELISA Kit
From: $1,364.00
Dulaglutide ELISA Kit
From: $1,364.00
Anti-Lenzilumab ELISA Kit
From: $1,364.00
Lenzilumab ELISA Kit
From: $1,364.00
Anti-Satumomab ELISA Kit
From: $1,364.00
Satumomab ELISA Kit
From: $1,364.00
Anti-Ibritumomab ELISA Kit
From: $1,364.00
Ibritumomab ELISA Kit
From: $1,364.00
Anti-Daclizumab ELISA Kit
From: $1,364.00
Daclizumab ELISA Kit
From: $1,364.00
Anti-Teplizumab ELISA Kit
From: $1,364.00
Teplizumab ELISA Kit
From: $1,364.00
Anti-Solanezumab ELISA Kit
From: $1,364.00
Solanezumab ELISA Kit
From: $1,364.00
Related Categories
Antibody Drug Development
RayBiotech has a comprehensive catalog of products and services to advance drug discovery, from off-the-shelf arrays to screen for drug candidates to custom assays and services.
ELISA Services
With our team of highly experienced scientists in our GLP-compliant laboratory, RayBiotech’s service department provides you with data of the highest accuracy and reproducibility.
RayPlex Bead Arrays
RayPlex™ utilizes the sandwich immunoassay principle, wherein a target protein is immobilized between a capture antibody on a microbead and a fluorescently-conjugated detection antibody.